375.72 0.00 (0.00%)
After hours: 4:59PM EST
|Bid||345.45 x 800|
|Ask||395.00 x 900|
|Day's Range||372.46 - 385.21|
|52 Week Range||281.89 - 416.49|
|Beta (3Y Monthly)||1.59|
|PE Ratio (TTM)||24.06|
|Earnings Date||Feb 6, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||426.05|
Moderna (NASDAQ:MRNA) went public on Dec. 7, raising $604 million on a market cap of $7.5 billion. The IPO met the goal, but a bad day on Wall Street sent the shares plummeting. It’s because Moderna represents the next wave in drug discovery. Like Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna is less a bet on particular drugs than on a method for finding them.
In the third quarter of this year, Regeneron Pharmaceuticals’ (REGN) selling, general, and administrative expenses rose YoY (year-over-year) to $369.23 million from $306.77 million, primarily due to a higher employee headcount. Meanwhile, its R&D (research and development) expenses rose YoY to $556.97 million from $529.75 million. It had R&D expenses of $2.03 billion and $2.23 billion, respectively, in fiscal 2018 and fiscal 2019, compared with $2.07 billion in fiscal 2017.
Regeneron Pharmaceuticals (REGN) offers products treating ophthalmic, cardiovascular, neuromuscular, inflammatory, and infectious diseases. In this series, we’ll explore Regeneron’s financials and valuation, and analysts’ views on its stock.
In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017. Meanwhile, peers Amgen (AMGN), Biogen (BIIB), and Johnson & Johnson (JNJ) are expected to have revenue of $23.36 billion, $13.31 billion, and $81.35 billion, respectively, in fiscal 2018. Regeneron’s cash per share is $20.14, while Amgen’s, Biogen’s, and Johnson & Johnson’s cash per share is $45.17, $21.31, and $7.20, respectively.
Year 2018 so far has been tough for the biotech sector. Let us take a look at four stocks that can be compelling choices for 2019.
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren’t very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]
The key driver behind the growth of biotech giant Regeneron Pharmaceuticals Inc. (REGN) may be facing competition, but not imminently. Right now, Regeneron's Eylea shares the top spot with Lucentis in the worldwide market for drugs to treat wet age-related macular degeneration (AMD). Lucentis is marketed by Novartis (NVS) outside North America and Roche (RHHBY) elsewhere in the world.
How Is Teva Pharmaceutical Positioned in 2018? On April 3, 2017, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of Austedo for chorea associated with Huntington’s disease. According to Teva Pharmaceutical’s third-quarter earnings conference call, almost 40,000 people in the US suffer from Huntington’s disease.
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / U.S. markets closed up on Monday as the U.S. and China came to an agreement of a 90-day trade war truce at the G-20 meeting in Argentina. The Dow Jones Industrial ...
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today presented new data for REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL), including promising clinical results in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) which are the two most common types of NHL. REGN1979 is a wholly-owned, investigational, full-length bispecific monoclonal antibody designed to trigger tumor killing by binding CD3 on immune system T-cells and CD20 on B-cell malignancies. Based on these data, Regeneron plans to initiate in 2019 a potentially registrational Phase 2 trial investigating REGN1979 in R/R FL.
I’ve been keeping an eye on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) because I’m attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believe Read More...
The stock market correction that started in October and has continued in November will encourage investors to buy more conservative stocks. Conversely, Pfizer Inc. (NYSE: PFE) stock is closer to its 52-week highs. Plus, Pfizer stock has a dividend yield of around 3%.
TARRYTOWN, N.Y. , Nov. 20, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast its management presentation at the Piper Jaffray 30 th Annual Healthcare Conference at 11:00 ...
Glaxo (GSK) submits sBLA to the FDA seeking label expansion of its asthma drug, Nucala, in pediatric patients in the United States.
Using recent actions and grades from TheStreet's Quant Ratings and layering on technical analysis of the charts of those stocks, Trifecta Stocks identifies five names each Friday that look bearish. While we will not be weighing in with fundamental analysis we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. recently was downgraded to Hold with a C+ rating by TheStreet's Quant Ratings.
Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.